



RENX to present at 39th JP Morgan Healthcare Conf.

January 4, 2021
RNS Number : 3438K
Renalytix AI PLC
04 January 2021

Renalytix AI plc

("RenalytixAI" or the "Company")

RenalytixAI to Present at the 39th Annual J.P. Morgan Healthcare Conference

NEW YORK, 4 January 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the Company will be presenting at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.

RenalytixAI's management is scheduled to present on Wednesday, January 13 at 10:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at investors.renalytixai.com.

For further information, please contact:

Renalytix AI plc www.renalytixai.com

James McCullough, CEO Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600

Alex Price / Nicholas Moore

Investec Bank plc (Joint Broker) Tel: 020 7597 4000

Gary Clarence / Daniel Adams

Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical *in vitro* diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com.

Disclosure Information

Renalytix AI plc uses filings with the Securities and Exchange Commission, its website (www.renalytixai.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRABXGDBGXGDGBB